Key Takeaways
- Domestic business surged 42% YoY, with organic growth in mid-teens and acquired brands up 34% like-for-like; JB was the fastest-growing top-25 pharma company for the second straight year.
- CDMO revenues nearly doubled to Rs. 100 crores, driven by cough & cold lozenge demand; management set a 3-year aspiration for the segment to reach 20% of total revenue.
- Gross margins compressed to 62.3% from 65% last year on cost inflation and higher Azmarda sales, but local sourcing and easing China costs underpin a guided recovery toward 64% and northwards.
- Azmarda's 50% price cut was planned at acquisition; volume already up 1.25x to 1.3x versus pre-LOE, and a new cost-effective sourcing model is in place to protect unit economics.
- What to watch next quarter: Whether gross margins begin their promised inch-up, the pace of CDMO order book conversion, and any demand impact from South Africa's public-sector competitive pressures.
Domestic Formulations: The Growth Engine
- Broad-based outperformance: Domestic business hit Rs. 407 crores, with organic growth in mid-teens and the acquired portfolio contributing 34% like-for-like growth per IQVIA. JB repeated as the fastest-growing company in the IPM top 25.
- Cardiology ascendant: With Cilacar, Nicardia, Azmarda, and the newly acquired Razel, JB entered the top 10 companies by sales in cardiology and was the fastest-growing among those top 10 players.
- Chronic mix shift underway: Chronic contribution to India business is close to 50%, with a stated intention to reach close to 60% in the short to midterm. New product contribution rose to ~5% of sales from 1.5% in October 2020.
- Prescription momentum intact: JB ranks 15th by prescriptions versus 22nd or 23rd by value, suggesting headroom to convert prescriber breadth into revenue. MR productivity is tracked through prescription momentum, and feet-on-the-street additions will be marginal, focused on pockets and territories.
- Cardiac/diabetes market slowdown is price-led, not volume-led: Big molecules and brands faced price pressure, but prescriptions continue to increase and have surpassed pre-COVID levels, with patient compliance significantly improved. Some large single molecules are being substituted by FDCs as doctors treat comorbid patients and cost of therapy matters.
Kunal Khanna: "The slowdown is attributed to a few things which are not completely volume based. There have been big molecules and big brands which have been subject to price pressure which has led to a slowdown in the recent past. With respect to offtake of the molecules, patient adoption, or the compliance rates, systemically there is nothing really changing in the market."
Azmarda & the LOE Playbook
- Price cut was priced into the deal: Management was certain at acquisition that price erosion would occur and was prepared with a target positioning price. The 50% reduction announced in December triggered a volume uptick of 1.25x to 1.3x versus the pre-LOE scenario within the first month.
- Cost model reset in parallel: A new cost-effective sourcing model for Azmarda has been activated, which together with easing intermediate costs from China supports the guided gross margin recovery.
- Brand traction: Azmarda saw 50% growth and entered the IPM top 300 list at rank 270, demonstrating that the volume ramp is already compensating for the price headwind.
Kunal Khanna: "When we actually looked at this acquisition, we were very certain that there is going to be price erosion in the market. And we were quite prepared in terms of at what price we will be positioning our product... The scenario for us has not changed from what we initially envisaged in terms of how the market will shape up."
CDMO: The 20% Aspiration
- Near-doubling of revenue: CDMO revenues grew 92% YoY to Rs. 100 crores, supported by an upsurge in anti-inflammatory and cough lozenges across Southeast Asia, Australia, New Zealand, and Canada.
- Three-year target: Management aspires for CDMO to contribute 20% of total revenue in 3 years, up from 12% currently. The Q4 order book is healthy and may stay close to the current run rate, with moderate growth expected next year.
- New lozenge pipeline: Proof-of-concept developed for lozenges in sleep disorders, motion sickness, and oral thrush, expected to see daylight in 8 to 12 months. Over a 2- to 3-year horizon, the portfolio expands into irritable bowel syndrome and additional concepts.
Nikhil Chopra: "This business today is contributing 12% to our revenue. Going ahead probably 3 years from here, this business should contribute 20% of our revenue."
International Business: Mixed Geographies, Steady Growth
- Overall performance: International business grew 23% YoY to Rs. 385 crores, with export formulations delivering their highest-ever sales. ROW and U.S. markets showed marked improvement, and Russia and CIS witnessed enhanced traction from cough & cold demand.
- South Africa caution: Public business is witnessing competitive pressures, and some demand impact is expected given geopolitical scenarios and economic uncertainty.
- ROW BGx pipeline: Progressive portfolio launches expected in H2 of next year across Sub-Sahara Africa, Latin America, Southeast Asia, and the Middle East, with teams working on bioequivalence filings.
- U.S. strategy remains niche: JB is a small player working to its strengths in extended-release and modified-release technologies, including OROS. Three new ANDA filings were made in the last 4 to 5 months, with commercial availability expected in 12 to 18 months. The model is costless, working with partners.
Nikhil Chopra: "What has been spoken in the world of U.S. business is we are a very small fish in a big point. So, we conceptually are working in accord to our strengths in terms of the products that we manufacture based on the technology backup that we have got, be it extended release, modified release."
Margins: The Recovery Thesis
- Gross margin compression: Gross margins at 62.3% versus 65% last year, hit by cost inflation and higher Azmarda sales during the quarter. Other expenses improved to 22.8% of sales from 24.5%, providing some offset.
- EBITDA margin: Operating EBITDA margin at 24.3% versus 25.5% YoY. Depreciation was higher due to an Rs. 11 crore amortization charge on acquired brands, with a marginal step-up expected from the Razel acquisition.
- Recovery path: Intermediate costs from China are easing, the Europe situation is expected to improve, and local sourcing of Azmarda is activated. Management sees gross margins inching toward 64% and northwards, with Q4 staying in the current range and the build happening more toward Q1 and beyond.
- Operating leverage: Operating leverage is expected to increase as the business moves forward, with an endeavor to lift operating margin next year versus this year.
Kunal Khanna: "And with the local sourcing of Azmarda already being activated, we see our gross margin profile inching upwards towards 64% and northwards moving ahead."
Portfolio & Productivity Levers
- Sanzyme/probiotic growth: The market is growing at 12% to 14%, but JB delivered +20% growth for two consecutive quarters because the asset was under-penetrated and under-represented. JB improved penetration and presence, leveraged synergy with antibiotic prescribing via its gastroenterologist foothold, and executed life cycle management with Sporlac GG for pediatric and Sporlac Eva for women health.
- No need for headcount expansion: Management sees no need to add people to the Sanzyme field force; the plan is to penetrate better, widen the portfolio, and meet the same set of doctors to enhance productivity. Cost synergy benefits are expected to continue into FY24.
- NLEM exposure reduced: With ranitidine out of NLEM, exposure is now closer to 12% to 13%, down from 30%+ previously, reducing price-control risk.
- Metrogyl and Rantac: Both products were flat in volume terms over the last 6 months, with seasonal demand expected from March through July-August.
- API business: Down ~4% YoY due to offtake patterns after a significant uptick in Q3 last year. Q4 is expected to cover the muted Q3 offtake, and the business will end with moderate growth.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic growth | Market-beating performance, close to mid-teen growth | Ongoing |
| International growth | Close to low double-digit growth | Ongoing |
| Gross margin recovery | Inch toward 64% and northwards; Q4 in current range, build from Q1 onward | Q1 FY24 and beyond |
| EBITDA margin | Upward from current standing; endeavor to improve next year vs this year | FY24 |
| Chronic contribution | Improve to close to 60% of India business from ~50% | Short to midterm |
| CDMO revenue contribution | Reach 20% of total revenue from 12% currently | 3 years |
| CDMO new lozenge products | Proof-of-concept launches in sleep disorders, motion sickness, oral thrush | 8 to 12 months |
| ROW BGx launches | Progressive portfolio launches in Sub-Sahara Africa, Latin America, Southeast Asia, Middle East | H2 next year |
| U.S. ANDA commercialization | 3 recent filings commercially available | 12 to 18 months |
| Cost synergies | More benefits from acquired portfolio integration | FY24 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹793 cr, +32% YoY |
| Domestic revenue | ₹407 cr, +42% YoY |
| Organic domestic growth | Mid-teens YoY |
| International revenue | ₹385 cr, +23% YoY |
| International revenue constant currency growth | 17% to 18% YoY |
| Gross margin | 62.3%, vs 65% in FY22 and close to last quarter |
| Operating EBITDA (before ESOP) | ₹193 cr, +26% YoY |
| Operating EBITDA margin | 24.3%, vs 25.5% in Q3 FY22 |
| Profit after tax | ₹106 cr, +26% YoY |
| CDMO revenue | ₹100 cr, +92% YoY |
| CDMO revenue contribution | 12% of total revenue |
| New product contribution to domestic business | Close to 5%, up from 1.5% in Oct 2020 |
| Domestic volume growth | 4% to 5% |
| Domestic price growth | Close to 7% to 8% |
| Chronic contribution to India business | Close to 50% |
| NLEM portfolio exposure | Closer to 12% to 13% |
| Total MR strength | Close to 2,500 |
| Company average MR productivity | Close to ₹0.65 cr per MR per year |
| Net debt | ₹571 cr debt, ₹142 cr cash and investments |
| Blended cost of debt | Closer to 8.1% to 8.2% |
| Interim dividend | ₹8.5 per share |